期刊
LANCET INFECTIOUS DISEASES
卷 14, 期 2, 页码 146-159出版社
ELSEVIER SCI LTD
DOI: 10.1016/S1473-3099(13)70266-4
关键词
-
资金
- AXA Research Fund
- French Government [ANR-10-LABX-62-IBEID]
- Schering-Plough
- Ministerio de Economia y Competitividad
- Instituto de Salud Carlos III
- European Development Regional Fund [REIPI RD12/0015]
- Department of Veterans Affairs
- Biomedical Research Institute of New Mexico
Use of totally implantable venous-access ports (TIVAPs) is standard practice for patients with diseases such as solid-tumour cancers, haematological malignancies, and chronic digestive diseases. Use of TIVAPs allows long-term administration of venotoxic compounds, improves patients' quality of life, and reduces the risk of infection. Microbial contamination, formation of pathogenic biofilms, and infection, however, are associated with morbidity, mortality, and increased health-care costs. Local and systemic complications or infections related to specific pathogens might lead to device removal. Alternatively, conservative treatment with combined systemic antibiotics and antibiotic lock therapy might be useful. We discuss in-vitro and in-vivo basic and clinical research findings on the epidemiology, diagnosis, and prevention of TIVAP-related infections, the current challenges to management, promising strategies, and some treatments in development that are likely to improve outcomes of TIVAP-related infections, with a particular focus on antibiotic lock therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据